Publication

Management of coagulation abnormalities in liver disease

Potze, W., Porte, R. J. & Lisman, T., Jan-2015, In : Expert Review of Gastroenterology & Hepatology. 9, 1, p. 103-114 12 p.

Research output: Contribution to journalReview articleAcademicpeer-review

Liver disease is characterized by changes in all phases of hemostasis. These hemostatic alterations were long considered to predispose patients with liver disease towards a bleeding tendency, as they are associated with prolonged conventional coagulation tests. However, these patients may also suffer from thrombotic complications, and we now know that the hemostatic system in patient with liver disease is, in fact, in a rebalanced state. In this review we discuss the concept of rebalanced hemostasis and its implications for clinical management of patients with liver disease. For instance, there is no evidence that the use of prophylactic blood product transfusion prior to invasive procedures reduces bleeding risk. Clinicians should also be aware of the possibility of thrombosis occurring in patients with a liver disease, and regular thrombosis prophylaxis should not be withheld in these patients.

Original languageEnglish
Pages (from-to)103-114
Number of pages12
JournalExpert Review of Gastroenterology & Hepatology
Volume9
Issue number1
Publication statusPublished - Jan-2015

    Keywords

  • anticoagulants, bleeding, bleeding management, coagulation, coagulation tests, hemostasis, liver disease, thrombin generation, thrombosis, thrombosis management, FRESH-FROZEN PLASMA, MOLECULAR-WEIGHT HEPARIN, THROMBIN-ACTIVATABLE FIBRINOLYSIS, RECURRENT VENOUS THROMBOEMBOLISM, HOSPITALIZED CIRRHOSIS PATIENTS, RECOMBINANT FACTOR VIIA, VON-WILLEBRAND-FACTOR, REDUCES BLOOD-LOSS, TRANSFUSION REQUIREMENTS, CLINICAL CONSEQUENCES

ID: 17417378